Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Current Deferred Revenue (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Current Deferred Revenue for 9 consecutive years, with $10.6 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 84.86% to $10.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.6 million through Dec 2025, down 84.86% year-over-year, with the annual reading at $10.6 million for FY2025, 84.86% down from the prior year.
  • Current Deferred Revenue hit $10.6 million in Q4 2025 for Sutro Biopharma, up from $9.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $74.0 million in Q2 2024 to a low of $5.5 million in Q4 2021.
  • Historically, Current Deferred Revenue has averaged $24.8 million across 5 years, with a median of $16.3 million in 2022.
  • Biggest five-year swings in Current Deferred Revenue: soared 310.09% in 2024 and later plummeted 87.63% in 2025.
  • Year by year, Current Deferred Revenue stood at $5.5 million in 2021, then surged by 204.93% to $16.8 million in 2022, then increased by 23.31% to $20.7 million in 2023, then surged by 237.67% to $69.8 million in 2024, then tumbled by 84.86% to $10.6 million in 2025.
  • Business Quant data shows Current Deferred Revenue for STRO at $10.6 million in Q4 2025, $9.0 million in Q3 2025, and $12.0 million in Q2 2025.